PharmaCyte Biotech Announces 1-for-19 Reverse Stock Split to Regain Nasdaq Listing Compliance
PharmaCyte Biotech, Inc., a biotechnology company, has announced that its board of directors has approved a 1-for-19 reverse stock split of the company’s common stock. The reverse stock split is scheduled to take effect on November 12, 2026, following approval by the company’s stockholders at its annual meeting held earlier this year. The move is intended to increase the market price per share of PharmaCyte’s common stock and help the company regain compliance with Nasdaq’s minimum bid price requirement for continued listing on The Nasdaq Capital Market.
PharmaCyte Biotech, Inc. (Nasdaq: PMCB), referred to as “PharmaCyte” or the “Company,” announced that its board of directors has formally approved a reverse stock split of the company’s issued and outstanding common stock at a ratio of 1-for-19. Under the approved arrangement, every 19 shares of existing common stock will be consolidated into one share of common stock. The company stated that the reverse stock split will become legally effective at 4:01 p.m. Eastern Time on November 12, 2026.
The decision follows stockholder approval obtained during PharmaCyte’s annual meeting of stockholders on March 30, 2026. With the required approval from stockholders already secured, the company’s board has proceeded with implementing the reverse stock split as part of its efforts to address Nasdaq’s continued listing requirements.
Following the implementation, PharmaCyte’s common stock is expected to begin trading on a split-adjusted basis on November 13, 2026, on The Nasdaq Capital Market. The company will continue trading under its existing ticker symbol, “PMCB,” but its shares will be assigned a new CUSIP number, 71715X 302, to reflect the corporate action.
The reverse stock split represents an important capital markets measure for PharmaCyte as it seeks to improve the per-share trading price of its common stock. By consolidating the outstanding shares, the company aims to increase its stock price and regain compliance with Nasdaq’s minimum bid price requirement, which is necessary to maintain its listing on The Nasdaq Capital Market.
Reverse Stock Split Approved at a 1-for-19 Ratio
Under the terms of the reverse stock split, every 19 shares of PharmaCyte common stock held by an investor immediately before the effective time will automatically be converted into one share of common stock after the transaction takes effect.
For example, a stockholder holding 1,900 shares before the reverse stock split will hold 100 shares following the consolidation. Similarly, an investor with 950 shares will hold 50 shares after the adjustment. The conversion will be applied automatically to all eligible shares, subject to the company’s procedures for handling fractional shares.
A reverse stock split consolidates multiple existing shares into a smaller number of shares without changing the proportionate ownership interest of stockholders, except for adjustments associated with fractional share treatment. Although the number of shares held by investors will decrease, the transaction is designed to correspondingly increase the market price per share, based on the prevailing market valuation.
PharmaCyte emphasized that no fractional shares will be issued as part of the reverse stock split. When the consolidation results in a stockholder being entitled to a fractional share, the company will instead provide a cash payment in lieu of issuing that fraction.
The cash payment will be calculated by multiplying the fractional share amount that the stockholder would otherwise have received by the closing sales price of PharmaCyte common stock on The Nasdaq Capital Market on November 12, 2026. This date represents the final trading day before the company’s common stock begins trading on a split-adjusted basis.
The payment calculation will take into account the reverse stock split adjustment, ensuring that eligible stockholders receive cash equivalent to the value of the fractional share entitlement under the company’s stated procedure.
This approach will allow the company to complete the share consolidation without issuing fractional ownership interests. It will also provide a consistent mechanism for compensating stockholders whose holdings do not convert into whole shares under the 1-for-19 ratio.
Outstanding Share Count to Decline Significantly
One of the primary effects of the reverse stock split will be a substantial reduction in the total number of outstanding shares of PharmaCyte common stock.
As of November 11, 2026, the company had approximately 10,755,649 shares of common stock outstanding. Following implementation of the 1-for-19 reverse stock split, the outstanding share count is expected to decrease to approximately 566,087 shares.
This reduction reflects the consolidation of 19 existing shares into one new share. The adjustment will affect the number of shares held by individual investors and the company’s overall outstanding common stock balance.
Importantly, PharmaCyte stated that the total number of authorized shares of common stock will remain unchanged following the reverse stock split. Therefore, while the number of issued and outstanding shares will be reduced, the company’s authorized share capacity will not be proportionally decreased.
The distinction between authorized and outstanding shares is important when assessing the overall impact of a reverse stock split. Outstanding shares represent the shares currently issued and held by stockholders, whereas authorized shares represent the maximum number of shares the company is permitted to issue under its corporate authorization.
By maintaining its existing authorized share limit, PharmaCyte will preserve its authorized capital structure while reducing the number of shares currently outstanding through the consolidation.
The company also confirmed that the reverse stock split will not independently change the overall authorized number of shares. The principal adjustment will apply to the outstanding common stock and other securities or arrangements linked to the company’s share structure.
Adjustments to Stock Options, Warrants and Convertible Securities
In addition to the direct consolidation of common stock, PharmaCyte will make proportional adjustments to certain outstanding equity-based and convertible securities to reflect the reverse stock split.
These adjustments will apply to the exercise prices and conversion prices associated with the company’s outstanding stock options, warrants and convertible securities. The number of shares underlying these instruments will also be adjusted proportionally to account for the 1-for-19 consolidation ratio.
Such adjustments are generally necessary to preserve the economic relationship between the underlying securities and the company’s common stock following a reverse stock split.
For example, when the number of shares available through an outstanding stock option or warrant is reduced under the reverse split, the corresponding exercise price will be adjusted proportionally. Similarly, the conversion terms of convertible securities will be modified to reflect the consolidated share structure.
Without these adjustments, the reverse stock split could unintentionally change the relative economic terms of outstanding equity awards and convertible instruments. Proportional adjustments are therefore intended to maintain the applicable relationships established under the original agreements.
PharmaCyte also confirmed that the number of shares issued or available for issuance under its stock incentive plans will be adjusted to reflect the reverse stock split.
Stock incentive plans are commonly used by biotechnology and pharmaceutical companies to attract, retain and motivate employees, executives, directors and other eligible participants. These plans may include stock options and other equity-based awards that provide recipients with an ownership interest or an opportunity to acquire company shares.
Following the consolidation, the applicable share amounts under PharmaCyte’s incentive plans will be revised proportionally. These changes will align the plans with the company’s new share structure while maintaining the intended proportional treatment of outstanding awards.
Nasdaq Listing Compliance Remains a Key Objective
PharmaCyte identified regaining compliance with Nasdaq’s minimum bid price requirement as the primary objective of the reverse stock split.
Companies listed on The Nasdaq Capital Market must satisfy applicable continued listing standards, including minimum bid price requirements. When a company’s stock trades below the required minimum price for the applicable compliance period, it may receive a deficiency notification and be required to take corrective action to maintain its listing.
A reverse stock split is one of the corporate actions companies may use to address a low per-share trading price. By reducing the number of outstanding shares, the transaction is intended to increase the market price of each individual share on a proportionate basis.
For PharmaCyte, the 1-for-19 reverse stock split is intended to raise the trading price of its common stock to a level that supports compliance with Nasdaq’s minimum bid price requirement.
However, a reverse stock split does not automatically guarantee a sustained increase in market value or ensure that a company will meet all applicable listing requirements. The actual market price following the transaction will continue to be influenced by investor demand, trading activity, market conditions and other factors affecting the company’s valuation.
The company will therefore need to maintain the required bid price in accordance with Nasdaq’s applicable rules following implementation of the reverse stock split.
Maintaining a listing on Nasdaq is important for publicly traded companies because it provides access to established capital markets and a broad investor base. Continued listing can also support stock liquidity, visibility among institutional and retail investors, and access to potential financing opportunities.
For biotechnology companies such as PharmaCyte, maintaining access to public capital markets can be particularly important because research, development and commercialization activities may require substantial financial resources over extended periods.
Trading Schedule and New CUSIP Information
PharmaCyte has provided a clear timeline for implementing the reverse stock split and transitioning its common stock to split-adjusted trading.
The reverse stock split will legally become effective at 4:01 p.m. Eastern Time on November 12, 2026. November 12 will also serve as the final trading day before the company’s common stock begins trading on a split-adjusted basis.
Beginning November 13, 2026, PharmaCyte common stock will trade on The Nasdaq Capital Market using the existing ticker symbol “PMCB.” However, the shares will carry a new CUSIP number, 71715X 302.
A CUSIP number is an identification code used to distinguish securities and facilitate the processing, settlement and clearing of financial transactions. Assigning a new CUSIP number reflects the change in the company’s share structure resulting from the reverse stock split.
Although the CUSIP number will change, investors will continue to identify PharmaCyte’s publicly traded common stock through the existing PMCB ticker symbol.
The transition to split-adjusted trading is expected to take place through the normal market infrastructure and brokerage processes.
Instructions for Stockholders
PharmaCyte has also outlined how the reverse stock split will affect stockholders based on the manner in which they hold their shares.
Investors who hold their shares electronically in book-entry form will not need to take any action to receive their post-split shares. Their positions will be automatically adjusted to reflect the new 1-for-19 share ratio.
Similarly, stockholders who own PharmaCyte shares through a bank, broker or another nominee will generally have their accounts automatically updated to reflect the reverse stock split. These investors will not be required to submit separate instructions or take additional steps to complete the conversion.
However, the company noted that the timing and processing of these adjustments may depend on the individual procedures followed by brokers and other financial intermediaries.
For stockholders who hold physical stock certificates, the process will involve additional instructions from PharmaCyte’s transfer agent, Equiniti Trust Company, LLC.
The transfer agent will provide information explaining how existing physical certificates can be exchanged for post-split shares. Depending on the applicable arrangements, stockholders may receive shares electronically in book-entry form or new physical certificates representing the adjusted number of shares.
Where applicable, investors will also receive cash payments in lieu of fractional shares resulting from the reverse stock split.
Stockholders holding physical certificates should review the instructions provided by Equiniti Trust Company, LLC and follow the required procedures to complete the exchange. Investors may also wish to contact their broker or the transfer agent if they have questions about how their individual holdings will be adjusted.
A Capital Structure Adjustment for PharmaCyte
The implementation of the 1-for-19 reverse stock split marks a significant adjustment to PharmaCyte Biotech’s common stock structure. By consolidating its outstanding shares, the company intends to increase its per-share trading price and address Nasdaq’s minimum bid price requirement.
The transaction will reduce the company’s outstanding common stock from approximately 10.76 million shares to approximately 566,087 shares, while leaving the total authorized share count unchanged. Adjustments will also be made to outstanding stock options, warrants, convertible securities and stock incentive plans to account for the revised share structure.
With the reverse stock split becoming effective on November 12, 2026, and split-adjusted trading scheduled to begin on November 13, PharmaCyte is moving forward with its stated objective of regaining compliance with Nasdaq’s continued listing standards.
The company will retain its PMCB ticker symbol, while its common stock will trade under the new CUSIP number 71715X 302. Most stockholders holding shares electronically or through brokerage accounts will not need to take action, while holders of physical certificates will receive exchange instructions from the company’s transfer agent.
The effectiveness of the reverse stock split in supporting Nasdaq compliance will depend on the company’s ability to meet the applicable minimum bid price requirement following the adjustment.